Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine DFMO
Study Type: Prevention
Phase: II
NCTID: NCT02679144
Principal Investigator:
Kevin Ginn
Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma
Study Type: Treatment
Phase: II
NCTID: NCT03115333
Principal Investigator:
Tolga Tuncer
Phase II Trial of Eflornithine/DFMO as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma
Study Type: Treatment
Phase: II
NCTID: NCT04696029
Principal Investigator:
Kevin Ginn
Feasibility Study of Resection and GammaTile Followed by Concomitant External Beam Radiation Therapy EBRT and Temozolomide TMZ and Adjuvant TMZ in Newly Diagnosed Glioblastoma GBM.
Study Type: Treatment
Phase: Feasibility/Pilot
NCTID: NCT05342883
Principal Investigator:
Tolga Tuncer
A Phase II Randomized Trial of Proton Vs. Photon Therapy IMRT For Cognitive Preservation in Patients with IDH Mutant, Low to Intermediate Grade Gliomas
Phase II Pediatric Study With Dabrafenib in Combination With Trametinib in Patients With HGG and LGG
Study Type: Treatment
Phase: II
NCTID: NCT02684058
Principal Investigator:
Kevin Ginn
A Phase II, Single-Arm Study of Bempegaldesleukin (Nktr-214) In Combination with Nivolumab In Cisplatin Ineligible, Locally Advanced or Metastatic Urothelial Cancer Patients
Study Type: Treatment
Phase: II
NCTID: NCT03785925
Principal Investigator:
Elizabeth Wulff-Burchfield
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma
Study Type: Other
Phase: N/A
NCTID: NCT00904241
Principal Investigator:
Keith August
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma
Study Type: Treatment
Phase: III
NCTID: NCT02176967
Principal Investigator:
Keith August
A Phase 2 Study of Veliparib ABT-888 and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma HGG without H3 K27M or BRAFV600 Mutations
Study Type: Treatment
Phase: II
NCTID: NCT03581292
Principal Investigator:
Kevin Ginn